Colitis is a chronic digestive disease typically a result of inflammation of the inner lining of the colon. There are multiple causes and forms of colitis but general inflammation is a common aspect to the condition. Cannabichromene (CBC) is a phytocannabinoid that may display certain anti-inflammatory abilities that could aid in the treatment and prevention of colitis. The key ability of CBC to affect the anti-inflammatory process is in the cannabinoids ability to activate the transient receptor potential ankyrin-type1 (TRPA1) while also inhibiting cannabinoid activation. [1]

A study dedicated to the effects of CBC and colitis focused on the effect of CBC on activated macrophages as they play an important role in the onset of inflammatory bowel disease (IBD) and colitis. By targeting macrophages, CBC showed the ability to ameliorate colonic inflammation in experimental colitis models. [1] In addition, the ability of CBC to regulate the abnormal responses of these macrophages may be a breakthrough for treatment of IBD. CBC also may inhibit gastrointestinal transit in experimental models of intestinal inflammation. [1]

This study shows that CBC directly reduces nitric oxide present in peritoneal macrophages and in vivo CBC treatments showed positive effects in therapeutically treating experimental colitis. By decreasing nitric oxide production, CBC can potentially limit intestinal tissue destruction brought on by the presence of NO in certain autoimmune diseases. The ability of CBC to effectively heal murine colitis in vivo also shows the cannabinoids potential to assist with the treatment of IBD.


  1. Romano, B., et al. The cannabinoid TRPA 1 agonist Cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. Brit Jour Pharmacol. January 2013.